ESC 365 - Professor Stefan Anker

Speaker illustration

Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

Member of:

Heart Failure Association

Stefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism at Charité Berlin. He obtained his MD (1993) from Charité Berlin, and his PhD (1998) from Imperial College London. Dr. Anker has authored more than 1,200 articles. He is named Highly Cited Researcher 2015–2022. Dr. Anker obtained a number of fellowships & grants, and for his work Dr. Anker has won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. Dr. Anker was awarded a Doctor honoris causa (Medical University Wroclaw / POL & Semmelweis University Budapest. Dr. Anker was Vice President of the ESC (2016-18) and President of the HFA of the ESC (2012-14). He was founding EiC of ESC Heart Failure (2014-22), and of JCSM (since 2010). Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (incl. FAIR-HF2, RESHAPE-HF2) as well as in the past (incl. EMPEROR-Preserved, FAIR-HF).

Sessions Presentations Events Articles

Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the outpatient setting

Event: ESC Congress 2023

Topic: Treatment

Session type: Satellite Symposium

Baroreflex activation therapy for HFrEF patients: long-term data and real-world experience

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Iron deficiency and the heart: what the cardiologist should know

Event: ESC Congress 2023

Topic: Anaemia/Iron Deficiency

Session type: Satellite Symposium

Management of worsening heart failure (WHF): latest advances

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Addressing unmet needs in acute heart failure - Emergency care and therapy optimization

Event: Heart Failure 2023

Topic: Acute Heart Failure

Session type: Satellite Symposium

Reducing hospitalisations and improving quality of life: why use cardiac contractility modulation (CCM)?

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Overcoming clinical inertia in chronic heart failure care - SGLT2 inhibition across the spectrum of ejection fraction

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Unlocking the potential of baroreflex activation therapy (BAT) for HFrEF patients

Event: ESC Congress 2022

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Satellite Symposium

HFpEF vs. HFrEF in patients with tricuspid regurgitation: does it matter for TTVr?

Event: ESC Congress 2022

Topic: Valvular Heart Disease

Session type: Satellite Symposium

SGLT2 inhibitors in practice (part 4): initiating heart failure treatment in hospital

Event: ESC Congress 2022

Topic: Chronic Heart Failure, Other

Session type: Satellite Symposium

ESC 365 is supported by